Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of br...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 710 0512

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

zampy Aug. 4 at 12:24 PM

$INMB So when we get approval in the UK APRIL 2027 here is the breakdiwn: 300 patients in UK RDEB....30X750K PER= 22M IN REVENUES/ 27M O/S = .82 CENTS E.P.S. X 20= $16 ( TAKING ONLY 10%) USA APPROVAL AUGUST 2027 3000 PATIENTS RDEB...SO TAKE 10% 300 patients x750k per= 220m in revenues/ 27m O/S = $8.20× 20= $160 INMB SHORT 2.6M ON 12M FLOAT SUBMISSION UK MAA MHRA SEPT/OCT ALL ABOUT CORDSTROM BURN ONLY 1M PER MONTH..CASH 21.5M TREAT SYSTEMATICALLY VS KRYS ONLY EXTERNALLY.... CONVICTION: STRONG BUY

1 · Reply

zampy Aug. 4 at 12:04 PM

$INMB 2s this week

0 · Reply

Muscle24 Aug. 3 at 8:29 PM

$INMB The most gorgeous YTD chart setup I have seen for years!!! A golden cross with an oversold RSI and an MACD slope moving upward from below the zero line! Yes, I’am more of technician than a fundamentalist! Here on $INMB, both, the technicals and fundamentals look good!!! Any positive updates regarding commercialization or BLA will send INMB soaring!!!! The last time I saw a biotech chart like that, $OTLK went from $0.40 to $1.85! Although OTLK is now down awaiting further confirmation from Management on how to move forward with their newly FDA approved drug.

1 · Reply

zampy Aug. 3 at 8:08 PM

$KRYS appears in my opinion new kid on the block $INMB treats systemically RDEB.....Perhaps the reason for softness lately my opinion...seems to be moving opposite directions.....

2 · Reply

RespectedElder Aug. 3 at 7:52 PM

$INMB steadily moving up. I’m glad. I overcommitted here a little. Maybe my hunch was right. I love the momentum and focus of the team and their community networking. The newly formed scientific advisory team is high caliber. These folks don’t waste their time with a BS board membership. That’s a signal on its own.

1 · Reply

Muscle24 Aug. 3 at 7:19 PM

$INMB 👀👀

0 · Reply

zampy Aug. 3 at 6:07 PM

$INMB Inverse relationship KRYS down again $375 to $306... INMB moving up nicely

0 · Reply

10baggerPete Jul. 31 at 2:04 PM

$INMB nice, but they need to raise cash or find a partner to advance their programs

2 · Reply

RespectedElder Jul. 31 at 1:41 PM

$INMB earnings and guidance on August 6

0 · Reply

RespectedElder Jul. 31 at 1:25 PM

$INMB $4.6 million non-dilutive cash received, Australia R&D Grant. Covers all of quarter’s cash needs. Nice surprise, and substantial where we are at. Almost 10% of market cap!

1 · Reply

INmune Bio receives $4.6M in rebates from Australia, UK

Jul 31, 2026, 7:00 AM EDT - 4 days ago

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

Jul 31, 2026, 7:00 AM EDT - 4 days ago

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

Jul 30, 2026, 7:00 AM EDT - 5 days ago

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

2026-07-20T11:05:18.000Z - 15 days ago

INmune Bio processes first umbilical cord tissue at CGT Catapult

Jul 20, 2026, 7:00 AM EDT - 15 days ago

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

Jul 15, 2026, 7:00 AM EDT - 20 days ago

INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

Jul 9, 2026, 7:00 AM EDT - 26 days ago

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC

2026-07-01T11:20:37.000Z - 4 weeks ago

INmune Bio advances CORDStrom platform patent application in the U.S.

Jul 1, 2026, 7:00 AM EDT - 4 weeks ago

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

2026-06-25T11:15:15.000Z - 5 weeks ago

INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan

Jun 25, 2026, 7:00 AM EDT - 5 weeks ago

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

2026-06-23T16:47:42.000Z - 5 weeks ago

INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting

Jun 23, 2026, 8:00 AM EDT - 6 weeks ago

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

Jun 16, 2026, 10:00 AM EDT - 6 weeks ago

INmune Bio Transcript: AGM 2026

2026-06-02T14:35:32.000Z - 2 months ago

INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial

Jun 2, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

Jun 2, 2026, 7:00 AM EDT - 2 months ago

INmune Bio Slides: Corporate presentation

2026-05-15T13:24:06.000Z - 2 months ago

INmune Bio publishes MINDFuL trial results in NPJ Dementia

May 15, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

2026-05-14T14:59:02.000Z - 2 months ago

INmune Bio receives fast track designation from FDA for XPro

May 14, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

May 13, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 3 months ago

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

May 5, 2026, 4:00 PM EDT - 3 months ago

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Apr 30, 2026, 8:00 AM EDT - 3 months ago

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

Apr 23, 2026, 8:00 AM EDT - 3 months ago

INmune Bio Proxy statement: Proxy filing

2026-04-16T14:16:48.000Z - 3 months ago

INmune Bio announces new preclinical data for INB03

Mar 30, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 4 months ago

INmune Bio Earnings release: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 4 months ago

INmune Bio Inc. Announces 2025 Results and Provides Business Update

Mar 24, 2026, 8:00 AM EDT - 4 months ago

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

2026-03-19T12:37:41.000Z - 4 months ago

INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s

2026-03-11T10:11:18.000Z - 5 months ago

INmune Bio upgraded to Buy from Neutral at Lucid Capital

Mar 10, 2026, 7:00 AM EDT - 5 months ago

INmune Bio Slides: Corporate presentation

Feb 26, 2026, 1:00 PM EST - 5 months ago

INmune Bio Transcript: Study update

Feb 23, 2026, 9:25 AM EST - 5 months ago

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

Feb 19, 2026, 12:15 PM EST - 5 months ago

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

2026-02-12T12:20:01.000Z - 6 months ago

INmune Bio announces FDA alignment on phase 2b/3 registration pathway

2026-02-10T13:12:07.000Z - 6 months ago

INmune Bio submits pre-submission package for CORDStrom with MHRA

Feb 10, 2026, 8:00 AM EST - 6 months ago

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

2026-01-27T14:30:16.000Z - 6 months ago

INmune Bio CEO says ‘well positioned for continued execution’

Jan 27, 2026, 9:25 AM EST - 6 months ago

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

2025-12-05T12:10:33.000Z - 8 months ago

INmune Bio publishes study on INmune’s CORDStrom platform

Dec 5, 2025, 7:00 AM EST - 8 months ago

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

2025-12-01T13:20:57.000Z - 8 months ago

INmune Bio announces neuroimaging data from Phase 2 MINDFuL trial

Dec 1, 2025, 8:00 AM EST - 8 months ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients

Nov 18, 2025, 8:00 AM EST - 9 months ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

2025-10-30T20:46:45.000Z - 9 months ago

INmune Bio reports Q3 EPS (24c), consensus (32c)

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Quarterly report: Q3 2025

Oct 30, 2025, 4:05 PM EDT - 9 months ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Oct 14, 2025, 8:00 AM EDT - 10 months ago

INmune Bio Proxy statement: Proxy Filing

Oct 14, 2025, 7:00 AM EDT - 10 months ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Oct 3, 2025, 8:00 AM EDT - 10 months ago

INmune Bio Proxy statement: Proxy Filing

2025-09-29T12:20:16.000Z - 11 months ago

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

2025-09-15T12:10:30.000Z - 11 months ago

INmune Bio completes first commercial manufacturing run of CORDStrom

2025-08-07T21:55:30.000Z - 1 year ago

INmune Bio CEO RJ Tesi retires, David Moss succeeds

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Slides: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 1 year ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jun 30, 2025, 4:05 PM EDT - 1 year ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Transcript: Status Update

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Press release: Status Update

Jun 30, 2025, 7:36 AM EDT - 1 year ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 1 year ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 12:16 PM EDT - 1 year ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 26, 2025, 4:00 PM EDT - 1 year ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

May 9, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q1 2025

May 8, 2025, 4:10 PM EDT - 1 year ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 25, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Apr 3, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Slides: Corporate Presentation

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Annual report: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Feb 12, 2025, 7:00 AM EST - 1 year ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 8:30 AM EST - 1 year ago

INmune Bio Transcript: Study Result

Feb 10, 2025, 7:00 AM EST - 1 year ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Dec 4, 2024, 9:00 AM EST - 1 year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q3 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 26, 2024, 8:00 AM EDT - 2 years ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 2 years ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 2 years ago

INmune Bio Announces $13.0 Million Registered Direct Offering

zampy Aug. 4 at 12:24 PM

1 · Reply

zampy Aug. 4 at 12:04 PM

$INMB 2s this week

0 · Reply

Muscle24 Aug. 3 at 8:29 PM

1 · Reply

zampy Aug. 3 at 8:08 PM

$KRYS appears in my opinion new kid on the block $INMB treats systemically RDEB.....Perhaps the reason for softness lately my opinion...seems to be moving opposite directions.....

2 · Reply

RespectedElder Aug. 3 at 7:52 PM

1 · Reply

Muscle24 Aug. 3 at 7:19 PM

$INMB 👀👀

0 · Reply

zampy Aug. 3 at 6:07 PM

$INMB Inverse relationship KRYS down again $375 to $306... INMB moving up nicely

0 · Reply

10baggerPete Jul. 31 at 2:04 PM

$INMB nice, but they need to raise cash or find a partner to advance their programs

2 · Reply

RespectedElder Jul. 31 at 1:41 PM

$INMB earnings and guidance on August 6

0 · Reply

RespectedElder Jul. 31 at 1:25 PM

$INMB $4.6 million non-dilutive cash received, Australia R&D Grant. Covers all of quarter’s cash needs. Nice surprise, and substantial where we are at. Almost 10% of market cap!

1 · Reply

zampy Jul. 31 at 11:51 AM

$INMB Great decision to shelve XPRO and focus on cordstrom.....We are soending only 1m to 1.5m per month as XPRO NO LONGER THE FOCUS. ALL ABOUT CORDSTROM and the 3.1m short on 12m float WILL SOON FIND OUT..

1 · Reply

bioinvestorrr Jul. 31 at 11:17 AM

INmune Bio Receives About $4.6M in R&D Rebates | INMB Stock News $INMB https://www.stocktitan.net/news/INMB/i-nmune-bio-receives-r-d-rebates-of-approximately-4-6-lwqf7lysw1tg.html

0 · Reply

bioinvestorrr Jul. 31 at 11:17 AM

$INMB INmune Bio Receives R&D Rebates of Approximately $4.6 Million -R&D rebates of ~$4.6 million received from Australia and UK -Combined rebates exceeded Q2 net cash used in operations after adjustment -Rebates are non-dilutive cash, avoiding additional equity issuance -Additional liquidity supports CORDStrom™ regulatory filings in UK/EU/US Supports XPro1595™ Phase 2b/3 registrational program in early Alzheimer’s NICE! Increased confidence with this one

1 · Reply

NachoBusiness Jul. 31 at 11:06 AM

$INMB Let’s see if it moves the needle

0 · Reply

TW_Research Jul. 30 at 5:22 PM

$INMB The newly established SAB is very strong in EB and MSCs as well. The opportunity for CORDStrom goes well beyond RDEB and this group is uniquely positioned to help INmune Bio. https://twresearchgroup.com/2026/07/inmune-bio-establishes-scientific-advisory-board-to-support-late-stage-development-and-expansion-of-cordstrom-platform/

1 · Reply

bioinvestorrr Jul. 30 at 11:36 AM

$INMB INmune Bio Forms CORDStrom Board; UK Filing Planned | INMB Stock News https://www.stocktitan.net/news/INMB/i-nmune-bio-establishes-scientific-advisory-board-to-support-late-eku5iqmieshk.html

0 · Reply

bioinvestorrr Jul. 30 at 11:36 AM

$INMB INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform New SAB to guide Ebstrocel Phase 3 and filings with global MSC and EB experts CORDStrom platform advancing to MAA/BLA with UK filing planned 2026 and EU/U.S. in 2027 Two late-stage platforms CORDStrom and XPro1595 both positioned for registrational development

1 · Reply

Muscle24 Jul. 29 at 6:11 PM

$INMB SUPER BULLISH !!

1 · Reply

RespectedElder Jul. 29 at 5:35 PM

$INMB A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology 2nd article came out today in Psychiatric Times https://www.psychiatrictimes.com/view/a-preventive-window-in-post-tbi-care-and-subsequent-alzheimer-pathology

0 · Reply

RespectedElder Jul. 28 at 2:47 AM

$INMB TBI and Alzheimer’s, XPRO 1595 Interview from today in Psychiatric Times <https://www.psychiatrictimes.com/view/preventing-alzheimer-disease-after-brain-injury-targeting-tnf-with-xpro1595>

0 · Reply

Muscle24 Jul. 27 at 11:08 PM

$INMB Super Bullishhh

0 · Reply

bioinvestorrr Jul. 27 at 8:41 PM

$INMB good close

1 · Reply

Market Cap	46.52M
Revenue (ttm)	50,000.00
Net Income (ttm)	-45.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-91,860.00%
Debt to Equity Ratio	0.00

Volume	222,600
Avg Vol	794,158
Day's Range	N/A - N/A
Shares Out	26.59M
Stochastic %K	65%
Beta	0.97
Analysts	Strong Sell
Price Target	$7.00